Close Menu

NEW YORK (GenomeWeb News) – The Ontario Institute for Cancer Research said today that it will collaborate with Johnson & Johnson company Janssen to conduct clinical trials aimed at identifying new prostate cancer biomarkers.

Under the multi-center collaboration, the partners will seek to unearth biomarkers that identify patients with hormone-resistant prostate cancer who are at high risk for disease progression and biomarkers for predicting how patients will respond to therapy.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.